Abbott
ABT
$98.49
-0.24%
Abbott Laboratories is a diversified global healthcare enterprise operating four core segments — Medical Devices (the largest at roughly $5.85B in quarterly sales), Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products — spanning cardiovascular rhythm management, point-of-care and molecular diagnostics, pediatric and adult nutrition, and generic branded medicines. As one of the largest and longest-tenured medical device and diagnostics franchises in the world, with a 54-year track record of consecutive dividend increases and a portfolio that spans hospital capital equipment to consumer self-tests, Abbott is best characterized as a defensive, cash-generative healthcare compounder rather than a high-growth disruptor. The current investor narrative is dominated by a sharp divergence between operational momentum and stock performance: the company beat on Q1 2026 earnings but cut full-year guidance, sending shares down roughly 27% over the trailing year even as revenue growth reaccelerated to 13% YoY in the June quarter. Bulls point to resilient Medical Devices growth, the strategic Exact Sciences acquisition, and a low 0.59 beta that makes the name a favored defensive holding amid renewed rate-hike fears, while bears focus on margin compression, a stretched payout ratio, and the guidance reset that has left the stock badly lagging the S&P 500.…
ABT
Abbott
$98.49
Related headlines
Investment Opinion: Should I buy ABT Today?
Rating: Hold with a bullish bias. The core thesis is that Abbott's 13% revenue growth, 16x forward PE, and $120.58 average analyst target offer an attractive risk/reward for patient investors, but the recent guidance cut and margin compression warrant caution until there is evidence of a turnaround. The consensus recommendation is "buy" with a mean rating of 1.52 (where 1 is strong buy), suggesting analysts see value at these levels.
Supporting evidence: Revenue grew 13.0% YoY in Q2 2026 to $12.59B, the strongest growth in several quarters. Free cash flow is robust at $8.72B trailing, supporting the 54-year dividend growth streak. The forward PE of 16.07x is well below the trailing 33.5x, implying expected EPS recovery to $8.28. The stock trades at a 23.7% discount to the average analyst target of $120.58, and the lowest target of $103 is still 5.6% above the current price. The debt-to-equity ratio of 0.289 and current ratio of 1.58 indicate a strong balance sheet.
Risks and conditions: The biggest risks are continued margin compression (Q2 operating margin fell to 14.15% from 18.42%), integration risk from the Exact Sciences acquisition, and further guidance cuts. This Hold would upgrade to Buy if operating margins stabilize above 16% for two consecutive quarters or if the stock drops below $85 (near the 52-week low) with no deterioration in fundamentals. It would downgrade to Sell if revenue growth decelerates below 8% or if free cash flow falls below $7B. Valuation verdict: The stock appears undervalued relative to its forward earnings power and analyst targets, but fairly valued to slightly expensive on trailing metrics given the earnings decline.
Sign up to view all
ABT 12-Month Price Forecast
Abbott presents a classic value-versus-momentum dilemma. The company's 13% revenue growth, robust free cash flow of $8.72B, and 54-year dividend history are undeniable strengths, and the forward PE of 16x suggests the market is pricing in a pessimistic scenario. However, the recent guidance cut, 47% decline in Q2 EPS, and 41.7% relative underperformance versus the S&P 500 indicate that near-term headwinds are real and may take several quarters to resolve. The analyst consensus remains bullish with a $120.58 target, but the stock's low beta means it will likely lag in a strong market. I would upgrade to bullish if operating margins show sequential improvement in Q3 2026 and revenue growth sustains above 10%. I would downgrade to bearish if the stock breaks below $85 or if free cash flow declines below $7B.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott's 12-month outlook, with a consensus price target around $120.72 and implied upside of +22.6% versus the current price.
Average Target
$120.72
0 analysts
Implied Upside
+22.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $135
Analyst target range
Bulls vs Bears: ABT Investment Factors
The bear case currently has stronger near-term evidence: the guidance cut, margin compression, and 41.7% relative underperformance are concrete, recent, and unresolved. However, the bull case rests on forward-looking fundamentals that are improving — 13% revenue growth, a 16x forward PE, and a $120.58 average analyst target imply the market is pricing in too much pessimism. The single most important tension is whether the margin compression in Q2 2026 is a temporary trough driven by the Exact Sciences integration and interest expenses, or the start of a structural profitability decline. If margins recover in the next two quarters, the stock likely re-rates toward analyst targets; if they don't, the 52-week low of $81.97 becomes the realistic downside anchor.
Bullish
- Revenue reaccelerated to 13% YoY: Q2 2026 revenue grew 13.0% year-over-year to $12.59B, a sharp acceleration from the 7.8% growth in Q1 2025. This suggests Abbott's core Medical Devices and Diagnostics franchises are regaining momentum after a prolonged post-COVID normalization period.
- Analyst consensus sees 24% upside: With 25 analysts covering the stock, the average price target is $120.58 versus the current $97.50, implying roughly 23.7% upside. The lowest target of $103 still sits above the current price, indicating a broad consensus that the sell-off has overshot fundamentals.
- Defensive low-beta profile: ABT's beta of 0.586 is well below the market's 1.0, meaning it historically declines only about 59% as much as the S&P 500 in down markets. In a macro environment where rate-hike fears are resurfacing, this low correlation makes ABT a favored defensive allocation.
- Fortress balance sheet and dividend: Debt-to-equity is just 0.289 and the current ratio is 1.58, providing ample liquidity. The company has raised its dividend for 54 consecutive years, with a 1.88% yield and a 63% payout ratio that remains sustainable given $8.72B in trailing free cash flow.
Bearish
- Guidance cut crushed investor confidence: Despite beating Q1 2026 earnings, Abbott cut full-year 2026 guidance, sending shares down roughly 27% over the trailing year. This guidance reset has left the stock badly lagging the S&P 500, with a relative strength of -41.7% over 12 months.
- Margin compression is real: Q2 2026 operating margin fell to 14.15% from 18.42% in Q2 2025, and net margin dropped to 7.37% from 15.97%. Gross margin improved slightly to 58.0%, but rising SG&A and interest expenses are eating into profitability.
- Earnings quality deteriorated sharply: Q2 2026 EPS was just $0.53, down 47.5% from $1.01 in Q2 2025, and net income fell 47.8% to $928M. The trailing PE of 33.5x on depressed earnings makes the stock look expensive on a trailing basis, and the PEG ratio is negative.
- Severe relative underperformance: ABT has underperformed the S&P 500 by 41.7% over the past year and by 34.4% year-to-date. The 1-month relative strength of -12.3% shows the weakness is accelerating, not stabilizing, which could trigger further institutional selling.
ABT Technical Analysis
Beta
0.58
0.58x market volatility
Max Drawdown
-39.6%
Largest decline past year
52-Week Range
$82-$135
Price range past year
Annual Return
-26.6%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -6.7% | +1.0% |
| 3m | +4.9% | +2.5% |
| 6m | -1.8% | +13.9% |
| 1y | -26.6% | +15.0% |
| ytd | -20.7% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Quarterly Revenue
$12.6B
2026-06
Revenue YoY Growth
+13.0%
YoY Comparison
Gross Margin
58.0%
Latest Quarter
Free Cash Flow
$8.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.9x
Enterprise Value Multiple
Investment Risk Disclosure
Abbott's financial risks are moderate but rising. The debt-to-equity ratio of 0.289 is conservative, but interest expense jumped to $299M in Q2 2026 from $121M a year earlier, a 147% increase that directly compressed net income to $928M. The payout ratio of 63% leaves limited room for further dividend increases if earnings remain depressed, and the trailing PE of 33.5x on $0.53 quarterly EPS means the stock is expensive on current earnings. Revenue concentration in Medical Devices (~46% of sales) exposes Abbott to hospital capital spending cycles and reimbursement pressure, while the Diagnostics segment remains vulnerable to post-COVID testing declines.
Market and competitive risks are significant. At a forward PE of 16.07x, ABT trades at a discount to the broader market but at a premium to some medical device peers on a trailing basis (33.5x). The beta of 0.586 provides downside protection, but it also means ABT will likely lag in a strong bull market — as evidenced by its 41.7% underperformance versus the S&P 500 over the past year. Competitive threats include intensifying competition in continuous glucose monitoring (where Abbott's FreeStyle Libre faces rivals like Dexcom) and in diagnostics from Roche and Siemens Healthineers. Regulatory risks, particularly around reimbursement and FDA approvals, are ever-present in healthcare.
The worst-case scenario would involve a continued decline in Medical Devices margins, a failed integration of Exact Sciences, and further guidance cuts that push EPS below the $7.77 low estimate. In that scenario, the stock could retest its 52-week low of $81.97, representing a 15.9% decline from the current $97.50. If the bear case fully materializes and the stock breaks below the 52-week low, the next support level would be around $75, implying a 23% downside. The maximum drawdown of -39.57% over the past year shows that such a move is not unprecedented.
FAQ
The most severe risk is continued margin compression — Q2 2026 operating margin fell to 14.15% from 18.42% a year earlier, and if this persists, earnings could miss the $8.28 consensus. Second, integration risk from the Exact Sciences acquisition could distract management and fail to deliver synergies. Third, competitive pressure in continuous glucose monitoring and diagnostics could erode Abbott's market share. Fourth, macro risk: while the low beta of 0.586 provides defense, a severe recession could reduce hospital capital spending and diagnostic testing volumes. Finally, the 63% payout ratio leaves little room for dividend increases if earnings remain depressed.
Our 12-month forecast has three scenarios: a base case (50% probability) with a target range of $103-$120, assuming revenue growth of 8-10% and margin stabilization; a bull case (30% probability) targeting $120-$135, driven by successful Exact Sciences integration and margin recovery; and a bear case (20% probability) targeting $82-$95, if margin compression persists and guidance is cut again. The most likely scenario is the base case, where the stock grinds higher toward the analyst average target of $120.58 as earnings normalize. The key assumption is that Q3 2026 results show sequential margin improvement.
On a forward basis, ABT appears undervalued. The forward PE of 16.07x is well below the trailing PE of 33.5x, reflecting expected EPS recovery to $8.28 in 2026. The price-to-sales ratio of 4.94 and EV/EBITDA of 19.5 are in line with large-cap medical device peers. However, on trailing metrics, the stock looks expensive due to depressed earnings — the trailing PE of 33.5x is above the market average. The market is pricing in a successful margin recovery and EPS normalization; if that fails to materialize, the stock could be fairly valued or even overvalued at current levels.
For long-term, income-focused investors, ABT is a reasonable buy at current levels given its 1.88% dividend yield, 54-year dividend growth streak, and 23.7% upside to the average analyst target of $120.58. The forward PE of 16.07x is undemanding for a company growing revenue at 13% YoY, and the low beta of 0.586 offers downside protection. However, the recent guidance cut and 47% decline in Q2 EPS mean near-term risks are elevated, and the stock could retest its 52-week low of $81.97 if margins don't improve. It is a good buy for patient investors with a 2-3 year horizon, but not for those seeking quick gains.
ABT is best suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company's low beta (0.586), consistent dividend growth (54 consecutive years), and essential healthcare products make it a classic buy-and-hold defensive name. Short-term trading is less attractive given the recent volatility and the lack of a clear catalyst until Q3 earnings. The stock's 41.7% underperformance versus the S&P 500 over the past year means mean reversion could take time. Investors should be prepared to hold through potential further downside to the $82-$95 range before realizing the upside to $120+.